The largest community of pharma leaders

IQVIA Named to FORTUNE’s 2020 List of “World’s Most Admired Companies”

DANBURY, Conn., & RESEARCH TRIANGLE PARK, N.C.–()–IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) has been named to FORTUNE magazine’s “World’s Most Admired Companies” list. IQVIA has received this distinction every year, since its inception, following the merger between IMS Health and Quintiles in 2016. IQVIA is recognized in FORTUNE’s Healthcare: Pharmacy and Other Services category with high marks regarding efficient use of corporate assets, management quality, effectiveness in conducting business globally, and long-term investment value.

“IQVIA is privileged to be on FORTUNE’s list of the World’s Most Admired Companies for the third consecutive year. This honor reinforces and recognizes the innovation and drive of our 65,000 employees around the world. Their work supports clients, providers, payers, and patients who benefit from our transformative advances in analytics and technology to improve healthcare outcomes,” said IQVIA Chairman and CEO Ari Bousbib.

FORTUNE’s World’s Most Admired Companies list is the definitive report card on corporate reputation. Since 1997, FORTUNE has identified, selected and ranked the World’s Most Admired Companies, identifying the business practices that make these companies highly regarded among their peers.

Most Admired Company Survey Methodology

FORTUNE collaborated with Korn Ferry on this survey of corporate reputation. They began with a universe of about 1,500 organizations comprising the 1,000 largest U.S. companies ranked by revenue, along with non-U.S. companies from FORTUNE’s Global 500 database that have revenues of $10 billion or more. The list was then winnowed to the highest-revenue companies within each industry, a total of 680 across 30 countries, and the top-rated companies were picked from that pool.

To determine the best-regarded companies spanning 52 industries, Korn Ferry asked executives, directors, and analysts to rate enterprises within their own industry on nine criteria, from investment value and quality of management and products to social responsibility and ability to attract talent. A company’s score had to rank in the top half of its industry peer group to be listed.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 65,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

IQVIAFIN

Click here to subscribe to Mobile Alerts for IQVIA.

Source

0FansLike
0FollowersFollow
0FollowersFollow
0FollowersFollow

Recent Articles

bioAffinity Technologies Announces Dr. Martin Tammemägi to Chair Scientific and Medical Advisory Board

SAN ANTONIO--(BUSINESS WIRE)-- #CyPathLung--bioAffinity Technologies, a privately held biotech company, today...

Evaluate Ltd. Launches Evaluate Omnium, Transforming Pharma’s Approach to Quantifying the Risk and Return of Novel Drugs

LONDON & BOSTON & TOKYO--(BUSINESS WIRE)-- #biopharma--Evaluate Ltd., the leading provider...

HCPLive® and the American Lung Association Unveil Exclusive Interview with Anthony S. Fauci, M.D.

CRANBURY, N.J.--(BUSINESS WIRE)-- #AnthonyFauci--Dr. Anthony Fauci joined Lungcast, the @MDMagazine and...

MedinCell Initiates the First Clinical Trial of Its Covid-19 Prevention Program

MONTPELLIER, France--(BUSINESS WIRE)--MedinCell (Paris:MEDCL): Access the complete press release About MedinCell...

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

SUZHOU, China--(BUSINESS WIRE)--CStone Pharmaceuticals (“CStone”, HKEX: 2616)] and Pfizer Investment Co....
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.